Allosteric antipsychotics: M4 muscarinic potentiators as novel treatments for schizophrenia

Neuropsychopharmacology

Volumn 35, Issue 4, 2010, Pages 851-852

  Farrell, Martilias ^a   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; G PROTEIN COUPLED RECEPTOR; LY 2033298; MUSCARINIC AGENT; MUSCARINIC M4 RECEPTOR; NEUROLEPTIC AGENT; NORCLOZAPINE; OXOTREMORINE; UNCLASSIFIED DRUG; XANOMELINE;

ALLOSTERISM; AVOIDANCE BEHAVIOR; DOPAMINERGIC SYSTEM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERHIDROSIS; NAUSEA; NEUROTRANSMISSION; NONHUMAN; NOTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SEIZURE; VOMITING;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; CELL LINE; HUMANS; MICE; RATS; RECEPTOR, MUSCARINIC M4; SCHIZOPHRENIA;

EID: 76749091482     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.206     Document Type: Note

References (11)

1. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A et al (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 54: 465-473.
2. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC et al (2008). Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105: 10978-10983.
3. Christopoulos A (2002). Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1: 198-210.
4. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005). The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psycho-pharmacology (Berl) 178: 451-460.
5. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001). Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 98: 15312-15317.
6. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J et al (1999). Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96: 10483-10488.
7. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB et al (2010). Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuro-psychopharmacology 35: 855-869.
8. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359.
9. Rowntree DW, Nevin S, Wilson A (1950). The effects of diiso-propylfluorophosphate in schizophrenia and manic-depressive psychosis. J Neurol Neurosurg 13: 47-62.
10. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD et al (2000). Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42: 249-259.
11. Snyder S, Greenberg D, Yamamura HI (1974). Antischizophrenic drugs and brain cholinergic receptors affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 31: 58-61.